bioAffinity Technologies (BIAF) Change in Accured Expenses (2021 - 2026)
bioAffinity Technologies (BIAF) reported Change in Accured Expenses of $310857.0 for Q1 2026, up 1210.72% year-over-year from $23716.5 in Q1 2025, and down 57.62% quarter-over-quarter from $733442.0 in Q4 2025.
bioAffinity Technologies (BIAF) Change in Accured Expenses (2021 - 2026) Analysis & Trends
bioAffinity Technologies (BIAF) has 6 years of Change in Accured Expenses data on file, last reported at $310857.0 in Q1 2026.
- Change in Accured Expenses for Q1 2026 came in at $310857.0, up 1210.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $658111.0 (up 35.02% YoY), and the FY2025 annual result was $319267.0, up 28.27% from the prior year.
- Change in Accured Expenses fell to $310857.0 in Q1 2026 per BIAF's latest filing, from $733442.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $733442.0 in Q4 2025 and troughed at -$399318.0 in Q4 2022.
- A 5-year average of $76904.8 and a median of -$27987.0 in 2025 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2025 and 2026: Change in Accured Expenses plunged 476.22% in 2025, then surged 1210.72% in 2026.
- A 5-year view of Change in Accured Expenses shows it stood at -$399318.0 in 2022, then jumped by 226.72% to $506025.0 in 2023, then fell by 2.28% to $494470.0 in 2024, then soared by 48.33% to $733442.0 in 2025, then plunged by 57.62% to $310857.0 in 2026.
- Business Quant data shows BIAF's Change in Accured Expenses at $310857.0 in Q1 2026, $733442.0 in Q4 2025, and -$63487.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Waters | 30,529.42 Bn | 30,528.96 Bn | 1.11 Bn | 235.00 Mn |
| 2 | Thermo Fisher Scientific | 183.75 Bn | 180.50 Bn | 7.74 Bn | - |
| 3 | Danaher | 133.13 Bn | 127.43 Bn | 3.59 Bn | -322.00 Mn |
| 4 | Idexx Laboratories | 46.14 Bn | 45.94 Bn | 722.74 Mn | - |
| 5 | Agilent Technologies | 38.20 Bn | 36.39 Bn | 990.00 Mn | - |
| 6 | Natera | 31.50 Bn | 30.40 Bn | 696.04 Mn | 98.23 Mn |
| 7 | Iqvia Holdings | 31.34 Bn | 29.36 Bn | 1.36 Bn | - |
| 8 | Illumina | 24.51 Bn | 23.36 Bn | 721.00 Mn | -47.00 Mn |
| 9 | Mettler Toledo International | 23.53 Bn | 23.47 Bn | 555.82 Mn | - |
| 10 | bioAffinity Technologies | 2.08 Mn | -1.02 Mn | - | 310,857.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 310,857.00 |
| Mar 31, 2026 | 310,857.00 |
| Dec 31, 2025 | 733,442.00 |
| Dec 31, 2025 | 733,442.00 |
| Sep 30, 2025 | -63,487.00 |
| Sep 30, 2025 | -63,487.00 |
| Jun 30, 2025 | -322,701.00 |
| Jun 30, 2025 | -322,701.00 |
| Mar 31, 2025 | -27,987.00 |
| Mar 31, 2025 | -27,987.00 |
| Dec 31, 2024 | 494,470.00 |
| Dec 31, 2024 | 494,470.00 |
| Sep 30, 2024 | -64,841.00 |
| Sep 30, 2024 | -64,841.00 |
| Jun 30, 2024 | 85,774.00 |
| Jun 30, 2024 | 85,774.00 |
| Mar 31, 2024 | -266,492.00 |
| Mar 31, 2024 | -266,492.00 |
| Dec 31, 2023 | 506,025.00 |
| Dec 31, 2023 | 506,025.00 |